Advertisement

Topics

Companies Related to "Switch turns immune cells tumor killing ability" [Most Relevant Company Matches] RSS

03:17 EDT 24th September 2018 | BioPortfolio

Here are the most relevant search results for "Switch turns immune cells tumor killing ability" found in our extensive corporate database of over 50,000 company records.

Showing "Switch turns immune cells tumor killing ability" Companies 1–25 of 2,000+

Extremely Relevant

Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine ...


Argos Therapeutics

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.a...

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...


Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

Gritstone Oncology, Inc.

Gritstone is a privately-held company developing personalized cancer immunotherapies to fight multiple cancer types. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors and deep financial backing to tackle fundamental challenges at the intersection of cancer g...

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...

Relevant

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell va...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Oncomatrix

Oncomatrix is focused on the development of new biopharmaceuticals targeting the tumor stroma. This innovative approach aims not to attack the tumor cells directly but rather the cells supporting the growth and invasiveness of the tumor.

NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

NantKwest, Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule d...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

Immune Design Corp.

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors,...

ActoKine Therapeutics

Cancer therapy using cytotoxic drugs or radiation has negative side effects on normal cells. To date, the pharmaceutical industry has not been able to produce a drug that can provide the dual functions of protecting normal cells while sensitizing tumor cells to cancer therapy. With consultation and guidance from industry experts, ActoKine will collaborate with international drug companies and inst...

OncoMab™ GmbH

OncoMab™ GmbH's business is the development of human antibodies for the treatment of cancer. The OncoMab™ way is unique because the antibodies are not developed in mice or by genetic engineering, but are isolated directly from cancer patients. The OncoMab™ antibodies are part of the innate natural immunity against malignant cells. This innate immune system functions as the first defence agai...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

DNAtrix Inc.

DNAtrix is a company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company with offices located in ...

Heat Biologics, Inc.

Heat Biologics (www.heatbio.com) (“Heat”) is a clinical-stage company immunotherapy company focused on developing its novel off-the-shelf “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) therapeutic vaccines to combat a wide range of cancers and other diseases. Heat’s ImPACT Therapy effectively reprograms tumor cells to “pump o...

Northwest Biotherapeutics

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against ...

Acceptys, Inc.

Acceptys is a private biotechnology company focused on the development of human antibody therapies in cancer and infectious diseases. The Company's key strength is its ability to directly leverage the power of the human immune system, which has continually evolved with the specific purpose of preserving health. More specifically, Acceptys can capture thousands of antibodies from strategically targ...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...

InNexus Biotechnology, Inc.

approaches that add secondary properties to monoclonal antibodies (binding is a primary property) and applies to virtually every antibody product currently in development. Adding these secondary properties can increase the potency of antibodies or add new properties such as the ability to penetrate into living cells.As an example, InNexus utilized SAT with a humanized monoclonal antibody, licensed...


More From BioPortfolio on "Switch turns immune cells tumor killing ability"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks